Hoth Therapeutics Inc

NASDAQ:HOTH  
1.30
-0.02 (-1.52%)
Products, Regulatory

Hoth Therapeutics Announces Positive Safety Results From Ad001 Cohort 1 Of Phase 1B Clinical Trial Of Biolexa For The Treatment Of Atopic Dermatitis

Published: 06/28/2021 12:37 GMT
Hoth Therapeutics Inc (HOTH) - Hoth Therapeutics Announces Positive Safety Results From Ad001 Cohort 1 of Phase 1b Clinical Trial of Biolexa for the Treatment of Atopic Dermatitis.
Hoth Therapeutics Inc - Primary Objectives Were Achieved in Cohort One.
Hoth Therapeutics Inc - Biolexa Was Well-tolerated With No Treatment Related Adverse Events.
Hoth Therapeutics Inc - Initiating Cohort 2 Patient Screening in September.